Jasper Therapeutics Inc (JSPR) 수입

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in enabling cures through hematopoietic stem cell therapy. The company is headquartered in Redwood City, California and currently employs 22 full-time employees. The company went IPO on 2019-11-20. The firm is focused on developing therapeutics targeting mast cell-driven diseases, such as Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU), and Asthma. The firm's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (c-Kit) receptor on mast and stem cells. Briquilimab is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the cell-surface receptor c-Kit, also known as CD117, thereby inhibiting signaling through the receptor. The SCF/c-Kit pathway is a survival signal for mast cells. The company is also developing briquilimab as a one-time conditioning therapy for severe combined immunodeficiency (SCID) patients undergoing a second stem cell transplant for which it is conducting a Phase 1/2 clinical trial.